BCAB
Price
$3.25
Change
+$0.09 (+2.85%)
Updated
May 3, 6:59 PM EST
3 days until earnings call
STOK
Price
$12.02
Change
+$0.33 (+2.82%)
Updated
May 3, 6:59 PM EST
One day until earnings call
Ad is loading...

BCAB vs STOK ᐉ Comparison: Which is Better to Invest?

Header iconBCAB vs STOK Comparison
Open Charts BCAB vs STOKBanner chart's image
BioAtla
Price$3.25
Change+$0.09 (+2.85%)
Volume$279.06K
CapitalizationN/A
Stoke Therapeutics
Price$12.02
Change+$0.33 (+2.82%)
Volume$307.92K
CapitalizationN/A
View a ticker or compare two or three
BCAB vs STOK Comparison Chart

Loading...

BCABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
STOKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
BCAB vs. STOK commentary
May 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Hold and STOK is a Hold.

COMPARISON
Comparison
May 06, 2024
Stock price -- (BCAB: $3.25 vs. STOK: $12.02)
Brand notoriety: BCAB and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 68% vs. STOK: 33%
Market capitalization -- BCAB: $156.35M vs. STOK: $626.45M
BCAB [@Biotechnology] is valued at $156.35M. STOK’s [@Biotechnology] market capitalization is $626.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $545.88B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 0 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than BCAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 4 bearish.
  • STOK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCAB is a better buy in the short-term than STOK.

Price Growth

BCAB (@Biotechnology) experienced а +27.95% price change this week, while STOK (@Biotechnology) price change was -3.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.95%. For the same industry, the average monthly price growth was -3.09%, and the average quarterly price growth was +64.80%.

Reported Earning Dates

BCAB is expected to report earnings on Aug 08, 2024.

STOK is expected to report earnings on Aug 05, 2024.

Industries' Descriptions

@Biotechnology (+3.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BCAB with price predictions.
OPEN
A.I.dvisor published
a Summary for STOK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
STOK($626M) has a higher market cap than BCAB($156M). STOK YTD gains are higher at: 128.517 vs. BCAB (32.114).
BCABSTOKBCAB / STOK
Capitalization156M626M25%
EBITDAN/AN/A-
Gain YTD32.114128.51725%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
BCABSTOK
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 6 days ago
78%
View a ticker or compare two or three
Ad is loading...
BCABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
STOKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLCCX20.100.38
+1.93%
Goldman Sachs Large Cap Gr Insghts C
ASICX24.650.33
+1.36%
Invesco EQV Asia Pacific Equity C
PCAQX73.970.88
+1.20%
Principal Capital Appreciation R5
FHEQX13.990.16
+1.16%
Federated Hermes SDG Engagement Eq A
SUGYX11.440.12
+1.06%
Pioneer Global Sustainable Growth Y

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with CTMX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then CTMX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
+2.85%
CTMX - BCAB
47%
Loosely correlated
-1.56%
STRO - BCAB
47%
Loosely correlated
-2.79%
CYTK - BCAB
43%
Loosely correlated
+1.45%
DNLI - BCAB
41%
Loosely correlated
+1.96%
AXON - BCAB
41%
Loosely correlated
+0.57%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with NUVB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then NUVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+2.82%
NUVB - STOK
49%
Loosely correlated
-1.53%
INZY - STOK
45%
Loosely correlated
+1.94%
QTTB - STOK
44%
Loosely correlated
-0.70%
STRO - STOK
43%
Loosely correlated
-2.79%
KOD - STOK
40%
Loosely correlated
+1.89%
More